Kiniksa insider sale notice: 58,424 shares listed

Kiniksa Pharmaceuticals insider sale notice for Class A Ordinary Shares.

Accepted by SEC EDGAR 05/01/2026 - 04:45 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals insider sale notice for Class A Ordinary Shares. The filing reports a broker-facilitated cashless exercise tied to an employee stock option on 05/01/2026 for 58,424 shares. It also reports a prior sale by John F. Paolini of 40,000 shares on 03/02/2026 for $1,792,970.00.

Key Figures

Planned shares sold: 58,424 shares Prior sale - Paolini: 40,000 shares Aggregate consideration: $1,792,970.00 +2 more

5 metrics

Planned shares sold 58,424 shares Employee Stock Option Exercise on 05/01/2026

Prior sale - Paolini 40,000 shares Sold on 03/02/2026 by John F. Paolini

Aggregate consideration $1,792,970.00 Proceeds reported for the 40,000-share sale on 03/02/2026

Reported outstanding-like figure 46,303,276 Numeric value appearing in the securities table (05/01/2026 row)

Additional numeric entry 3,137,710.00 Numeric value present in the securities section near share listings

Key Terms

Form 144, cashless exercise, Employee Stock Option Exercise, broker payment

4 terms

Form 144 regulatory

"Filer Information | 144: Filer Information"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

cashless exercise financial

"Broker Payment for Cashless Exercise"

A cashless exercise is a way for an option holder to convert stock options into actual shares without paying the purchase price in cash; instead they immediately give up a portion of the newly issued shares to cover the cost and any withholding taxes. Investors care because this process increases the number of shares available and can slightly dilute existing holdings, while also signaling how insiders or employees are realizing compensation without needing cash — similar to paying for a purchase by handing over part of what you just bought.

Employee Stock Option Exercise financial

"Employee Stock Option Exercise | Kiniksa Pharmaceuticals, Ltd."

broker payment financial

"Broker Payment for Cashless Exercise"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did KNSA's Form 144 disclose about the May 1, 2026 transaction?

It discloses a broker payment cashless exercise of employee stock options for 58,424 shares on 05/01/2026. The entry labels the method as an Employee Stock Option Exercise with a broker processing the cashless exercise.

Who reported sales in the filing and how many shares were sold?

The filing shows a sale by John F. Paolini of 40,000 shares on 03/02/2026. The reported aggregate consideration for that sale is $1,792,970.00 as disclosed in the record.

Does the Form 144 show the sale method for the reported transactions?

Yes. The May transaction is described as a Broker Payment for Cashless Exercise, and the March sale by Paolini is recorded as a sale through the listed broker or intermediary in the table entries.

What class of security is involved in these Form 144 disclosures?

Both transactions involve Class A Ordinary Shares. The filing specifically lists the security class and associates the May 1, 2026 entry with that share class.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001741533
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Kiniksa Pharmaceuticals International, plc
SEC File Number	001-38492
Address of Issuer	105 PICCADILLY, SECOND FLOOR LONDON UNITED KINGDOM W1J 7NJ
Phone	7814319100
Name of Person for Whose Account the Securities are To Be Sold	Paolini John F.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A Ordinary Share	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	58424	3137710.00	46303276	05/01/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A Ordinary Share	05/01/2026	Employee Stock Option Exercise	Kiniksa Pharmaceuticals, Ltd.			58424	05/01/2026	Broker Payment for Cashless Exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
John F. Paolini 105 PICCADILLY, SECOND FLOOR LONDON X0 W1J 7NJ	Kiniksa Pharmaceuticals International, plc	03/02/2026	40000	1792970.00

144: Remarks and Signature

Remarks
Date of Notice	05/01/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	11/18/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	John F. Paolini
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)